Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
AUSTIN, Texas, December 11, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the ...
Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...
MRD refers to cancer cells remaining post-treatment, undetectable by standard imaging, indicating potential recurrence risk. MRD testing methods include flow cytometry and genetic tests, offering ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) has emerged as a promising approach to identify individuals at high risk of ...
The FDA's Breakthrough Devices Program accelerates access to promising medical devices for serious conditions, ensuring safety and effectiveness through a rigorous review process. Haystack MRD test ...
MADISON, Wis. - Exact Sciences Corp. (NASDAQ:EXAS), a leader in cancer screening and diagnostic tests with a market capitalization of $10 billion, announced clinical validation data for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback